Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Preclinical Development

RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses

Manujendra N. Saha, Hua Jiang, Asuka Mukai and Hong Chang
Manujendra N. Saha
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hua Jiang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asuka Mukai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-10-0471 Published November 2010
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    A, structural formula of RITA [2,5-bis(5-hydroxymethyl-2-thienyl)furan] and nutlin [4-(4,5-bis-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl)-piperazin-2-one]. B, C, and D, RITA induces growth arrest and apoptosis of MM cells harboring wild-type p53. MM cells were plated in 96-well plates and cultured either with or without different concentrations of RITA (0.25–20 μmol/L). After 48 h, the cells were treated with MTT for 4 h at 37°C, and MTT activity was measured. Survival of the cells were expressed as percentage of the DMSO-treated control in cells harboring wild-type p53 (B) or mutant p53 (U266) or null p53 (8266R5) (C). Results represent the mean ± SD of three independent experiments done in triplicate. D, MM cells were treated with various concentrations of RITA (0.25–12.5 μmol/L) for 48 h. The cells were subsequently stained with FITC-Annexin V and propidium iodide and analyzed by flow cytometry. Each column represents the mean of apoptotic cells (Annexin V and propidium iodide positive) of three independent experiments after normalizing the data with vehicle treatment, and each bar represents SD.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    RITA induces activation of the p53 pathway in MM cells in a time-dependent manner. MM.1S (A) and H929 (B) cells were treated with 0.5 and 2.5 μmol/L RITA, respectively, at different time periods (4–24 h). Total cell lysates were prepared at the indicated hours after treatment of the cells with RITA and analyzed by Western blot for the indicated proteins. Data shown are representative of three independent experiments.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    RITA induces p53-dependent activation of the p53 pathway in MM cells in a dose-dependent manner. MM.1S (A), H929 (B), 8226R5 (C), and U266 (D) cells were treated with RITA for 6 hours at various concentrations (0.25–10 μmol/L). Total cell lysates were prepared and analyzed by Western blot for the expression of p53 and its transcriptional targets as well as apoptosis-associated proteins. Data shown are representative of three independent experiments.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    RITA induces caspase-dependent apoptosis in MM cells harboring wild-type p53. MM.1S or H929 cells were treated with 20 μmol/L pan-caspase inhibitor, Z-VAD-FMK, or 100 μmol/L caspase-8 inhibitor, Z-IETD-FMK, before treating the cells with RITA. A, after 6 h, cells were lysed and analyzed by Western blot for the expression of caspase-3 and/or caspase-8 and PARP. B, apoptosis was measured by flow cytometry in MM.1S and H929 cells treated with RITA in the presence or absence of Z-VAD-FMK or Z-IETD-FMK. Each column represents the mean of apoptotic cells (Annexin V–positive cells) of three independent experiments after normalizing the data with vehicle treatment, and each bar represents SD. *, significance at P < 0.02 by two-tailed t test. C, primary MM samples from four MM patients or BMMNC from two healthy volunteers were grown in normal growth medium. PBMNCs from three healthy volunteers were grown in the presence of 1% phytohemagglutinin. Cells were treated with escalating doses of RITA (0–20 μmol/L), and after 48 h, cell viability was measured by MTT assay.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    RITA and nutlin display synergistic cytotoxic effect in MM cell lines (A) and in primary MM samples (B). MM cells were seeded at 20 × 104/mL and were treated simultaneously with escalating doses of RITA and nutlin. After 48 h, cell viability was measured by MTT assay. CI value was calculated as described in Materials and Methods. C, a combination of RITA plus nutlin enhances killing of MM cells at 48 h as measured by flow cytometry. Graph represents data from three independent experiments. *, significance at P < 0.05 by two-tailed t test. Filled, empty, and hatched columns represent the percentage of apoptosis in nultin-, RITA-, or nutlin plus RITA–treated cells, respectively.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    RITA induces transcriptional regulation of a set of p53 target genes. A and B, microarray analysis of gene expression in MM.1S cells after 6 h treatment with RITA. The heat map of genes differentially expressed in MM cells. Vertical rows indicate separate arrays, and horizontal rows indicate genes. Values are normalized to untreated control. Green indicates low expression; red indicates high expression. C, mRNA levels of oncogenes were detected by qRT-PCR in MM.1S cells 6 h after treatment with 1 μmol/L RITA. Values were normalized to those obtained for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and expressed as log2-fold induction over DMSO-treated cells (mean ± SD).

Additional Files

  • Figures
  • Supplementary Daa, Saha, et al.

    Files in this Data Supplement:

    • Supplementary Table 1
PreviousNext
Back to top
Molecular Cancer Therapeutics: 9 (11)
November 2010
Volume 9, Issue 11
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses
Manujendra N. Saha, Hua Jiang, Asuka Mukai and Hong Chang
Mol Cancer Ther November 1 2010 (9) (11) 3041-3051; DOI: 10.1158/1535-7163.MCT-10-0471

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses
Manujendra N. Saha, Hua Jiang, Asuka Mukai and Hong Chang
Mol Cancer Ther November 1 2010 (9) (11) 3041-3051; DOI: 10.1158/1535-7163.MCT-10-0471
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • BMS-754807 Enhances Gemcitabine Response in PDAC
  • PSMA-Specific BiTE Antibody
  • BiKEs and TriKEs Enhance NK Cell Effector Function
Show more Preclinical Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement